ABSTRACT:
Acrivastine has a short biological half-life of 1.9 hour and having less bioavailability which necessitates multiple daily dosing hence the present study was aimed to develop a controlled release formulation of Acrivastine to reduce the dose related side effects and to reduce the dosage regimen. The present research project aimed to develop a Control release oral formulation of anticancer drug Acrivastine, Acrivastine used for the symptomatic relief of seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. Polymers like HPMC K4M, Carbopol 940 and HPMC K 15M were used for controlling the drug release, and the polymers are mixed in a predetermined ratio. Totally 9 formulations were prepared and evaluated for pre compression and post compression parameters, and all the results were found to be within the limits. From the drug and excipients compatability studies (FT-IR) it was confirmed that the drug and excipients used weren’t have any interactions. The in vitro dissolution studies revealed that the F9 formulation containing 150mg of HPMC K 15M controls the drug release up to 12 hours. So HPMC K 15M containing F9 formulation was considered to be suitable for the formulation of Acrivastine controlled release tablets at 150mg, and the drug release kinetics revealed that the F9 formulation shows super case transport mechanism.
Cite this article:
Nirmala Dasari, Retvik Chandra Padala, Sudhakar Muvva. Formulation and In vitro Evaluation of Acrivastine Controlled Release Tablets. Asian Journal of Pharmacy and Technology. 2023; 13(2):95-0. doi: 10.52711/2231-5713.2023.00018
Cite(Electronic):
Nirmala Dasari, Retvik Chandra Padala, Sudhakar Muvva. Formulation and In vitro Evaluation of Acrivastine Controlled Release Tablets. Asian Journal of Pharmacy and Technology. 2023; 13(2):95-0. doi: 10.52711/2231-5713.2023.00018 Available on: https://ajptonline.com/AbstractView.aspx?PID=2023-13-2-4
REFERENCES:
1. Liv J, Zhang F, Mc GinityJw. Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot – met extrusion. Eur J Pharm Biopharm, 2001l; 42: 181–190.
2. Brogden RN et al, Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders, 1991; 41(6):927-940
3. Xiaochen Gu et al, Evaluation and Comparison of Five Matrix Excipients for the Controlled Release of Acrivastine and Pseudoephedrine, 2004; 30(10), 1009-1017
4. Neittaanmäki H etal, Comparison of the New Antihistamine Acrivastine (BW 825C) versus Cyproheptadine in the Treatment of Idiopathic Cold Urticaria, 1988; 177(2), 98-103.
5. Robert J. Dockhorn MD et al, Efficacy of Acrivastine with Pseudoephedrine in Treatment of Allergic Rhinitis due to Ragweed, 1996; 76(2), 204-208.
6. Nair AB, Vyas H, Kumar A. Controlled release matrix uncoated tablets of enalapril maleate using hpmc alone. J Basic Clin Pharm. 2010; 1(2):71-5.
7. Shantveer V. Salger, Lingaraj S. Danki, Abdul Sayeed, Shivanand Hiremath.Formulation and invitro evaluation of sustained release matrixtablets of anti-hypertensive drug propranolol hydrochloride, Scholars Research Library, Der Pharmacia Lettre, 2010, 2(5): 12-22.
8. Amit.S.Yadav, Ashok Kumar P, Vinod R, Someshwara Rao B, Suresh V Kulkarni.Design and Evaluation of Guar Gum Based Controlled Release Matrix Tablets of Zidovudine, Journal of Pharmaceutical Science and Technology Vol. 2 (3), 2010, 156-162
9. Raj Kumar. Marikanti, Kiran Joshi. P, Vidya Sagar. CH, Venkateswara Reddy. B, Kiran kumar.A, Nagaraju.I, Srinivasa Rao. P1 and J. Ravi Kiran. Formulation and evaluation of controlled release matrix tablets of Trimtazidine Dihydrochloride, J. Chem. Pharm. Res., 2010, 2(3):746-753
10. Raju Manda, K Sundaramoorthy and T Vetrichelvan. Research Journal of Pharmaceutical, Biological and Chemical Sciences Formulation and In-Vitro Evaluation of sustained release Matrix Tabelts of Aceclofenac by using different natural polymars, ISSN: 0975-8585 October – December 2010
11. Priyanka Singh, Amit Kumar Shrivastava, Sachin Kumar, Manish Dhar Dwivedi. Formulation and Evaluation of Sustained Release Matrix Tablets of Aceclofenac. Borneo Journal of Pharmacy.2021, 4(2) 99-109.
12. Madhusmruti Khandai, Santanu Chakraborty, Anuradha Sharma, Debashisha Panda, Nazia Khanam, Santosh Kumar Panda. Development of propranolol hydrochloride matrix tablets: an investigation on effects of combination of hydrophilic and hydrophobic matrix formers using multiple comparison analysis. 2010; 1(2), 1-7.